Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials, Diabetes and Metabolism Journal (2019) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Patient assistance program, Novo Nordisk APC: Find a compounder, Alliance for Pharmacy Compounding (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Its important to note that Zepbound is most effective when used in conjunction with a reduced-calorie diet and regular physical activity
Compounded semaglutide and tirzepatide formulations are not FDA-approved and lack the clinical trial data of FDA-approved products
doi: 10.3390/nu16193245
Semaglutide also showed a 20% reduction in MACE in overweight or obese adults with preexisting ASCVD but without diabetes, according to the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial [7,8]
Semaglutide in Cedar Park, TX usually want more than a prescription